热门资讯> 正文
Wave Life Science股价上涨3.5亿美元
2025-12-10 14:53
- Wave Life Sciences (WVE) priced an upsized underwritten public offering of ~15.8M shares at a price to the public of $19.00 per ordinary share and pre-funded warrants to purchase up to 2.63M at $18.9999.
- Gross proceeds to Wave Life Sciences are to be ~$350M.
- The underwriters have a 30-day option to purchase up to an additional ~2.76M shares.
- The offering is expected to close on or about December 11, 2025.
More on Wave Life Sciences
- Wave Life Sciences Ltd. (WVE) Discusses Positive Interim Data from INLIGHT Trial of WVE-007 for Obesity Transcript
- Wave Life Sciences: Being Realistic, There Is Still So Much To Prove
- Wave Life Sciences Ltd. (WVE) Q3 2025 Earnings Call Transcript
- Wave Life Sciences upgraded at RBC following data for obesity asset WVE-007
- Wave Life Sciences announces $250M public offering and pre-funded warrants
推荐文章
打爆所有空头？Sandisk交出的“炸裂财报”再度引爆存储行情！周期或许远未见顶？
一周IPO | 新消费IPO再受热捧！鸣鸣很忙首日涨近70%；大族数控、爱芯元智等五只新股正在招股中
财报前瞻 | 4万亿美元市值迎大考！谷歌Q4财报能否为其“AI全栈”野心正名？
新股申购 | 两只新股今起招股！澜起科技一手入场费10796.80港元；爱芯元智一手入场费2848.44港元
华盛早报 | 特朗普今晚公布美联储新主席人选！沃什概率飙升至近8成；金银价格一度闪崩又回弹
美股机会日报 | Meta业绩亮眼盘前大涨9%！英伟达、微软等巨头被曝将向OpenAI投资600亿美元
港股突破28000点，接下来该如何布局？这三大方向尤获机构、北水青睐（附股）
微软Q2业绩会实录：大部分投入资本周期已通过合同锁定
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
